Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update

19 Jan 2026, 23:18 by Teresa Graham · The Cerbat Gem

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totaling 15,054,621 shares, an increase of 19.4% from the December 15th total of 12,612,667 shares. Approximately 15.6% of the company’s stock are sold short. Based on an average trading volume of 2,274,676 shares, the short-interest ratio is currently 6.6 days. Based on an average trading volume of 2,274,676 shares, the short-interest ratio is currently 6.6 days. Approximately 15.6% of the company’s stock are sold short.

Mind Medicine (MindMed) Stock Performance

NASDAQ:MNMD traded up $0.09 during trading hours on Monday, reaching $14.96. The stock had a trading volume of 2,053,792 shares, compared to its average volume of 2,191,259. The stock has a market cap of $1.47 billion, a P/E ratio of -7.33 and a beta of 2.57. The stock has a 50 day simple moving average of $12.83 and a 200 day simple moving average of $11.23. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. Mind Medicine has a 12-month low of $4.70 and a 12-month high of $15.29.

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.26). On average, research analysts forecast that Mind Medicine will post -1.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MNMD shares. Royal Bank Of Canada reduced their target price on Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Needham & Company LLC reissued a “buy” rating on shares of Mind Medicine (MindMed) in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a research report on Wednesday, October 8th. Jones Trading began coverage on Mind Medicine (MindMed) in a research note on Tuesday, December 23rd. They set a “buy” rating and a $61.00 target price on the stock. Finally, Chardan Capital raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a report on Wednesday, November 19th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $30.33.

Read Our Latest Analysis on Mind Medicine (MindMed)

Insider Transactions at Mind Medicine (MindMed)

In related news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares in the company, valued at $10,236,972.55. This represents a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Daniel Karlin sold 5,600 shares of Mind Medicine (MindMed) stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares of the company’s stock, valued at $5,589,078.75. This trade represents a 1.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 42,667 shares of company stock valued at $561,071 over the last three months. Corporate insiders own 2.45% of the company’s stock.

Institutional Trading of Mind Medicine (MindMed)

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. boosted its holdings in Mind Medicine (MindMed) by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. BIT Capital GmbH purchased a new stake in shares of Mind Medicine (MindMed) during the third quarter worth $26,000. CWM LLC boosted its holdings in shares of Mind Medicine (MindMed) by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Mind Medicine (MindMed) by 5,593.2% in the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after acquiring an additional 3,300 shares during the period. Finally, Sound Income Strategies LLC purchased a new position in shares of Mind Medicine (MindMed) in the third quarter valued at $46,000. Institutional investors own 27.91% of the company’s stock.

Mind Medicine (MindMed) Company Profile

(Get Free Report)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.